FinanceBuzz on MSN
Trump administration delays Medicare pilot program to cover weight-loss drugs - what to know
The BALANCE program was intended to cover weight-loss drugs for Medicaid beneficiaries, but is delayed. A new solution with ...
The deal involves Regeneron lowering the prices of all its current and future drugs on Medicaid, according to Trump. It also ...
WASHINGTON (AP) — The Food and Drug Administration commissioner's effort to drastically shorten the review of drugs favored by President Donald Trump's administration is causing alarm across the ...
WASHINGTON (AP) — The Food and Drug Administration commissioner's effort to drastically shorten the review of drugs favored by President Donald Trump's administration is causing alarm across the ...
Dr. Marty Makary, commissioner of the Food and Drug Administration, speaks at an event on addiction recovery in the Oval Office of the White House, Thursday, Jan. 29, 2026, in Washington, as Attorney ...
Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29 ...
As the Trump administration begins to make its mark on the Medicare drug price negotiation program and pursue its own policies on prescription drugs, litigation over program continues. In the two ...
On April 15, 2025, President Trump signed the Lowering Drug Prices by Once Again Putting Americans First Executive Order (Executive Order). The Executive Order revives and expands several ...
Court blocks Trump administration's drug rebate program for safety-net hospitals Judges cite lack of impact consideration on hospitals Inflation Reduction Act allows Medicare drug price negotiations ...
WASHINGTON – The U.S. Food and Drug Administration on Sunday began accepting requests to participate in its PreCheck pilot program, designed to boost domestic drug supply by speeding up construction ...
WASHINGTON — The Food and Drug Administration commissioner’s effort to drastically shorten the review of drugs favored by President Trump’s administration is causing alarm across the agency, stoking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results